ECTRIMS 2014

The 2014 Joint ACTRIMS-ECTRIMS MSBoston Meeting will take place on September 10-13 in Boston, MA. The conference will include sessions that address various aspects of multiple sclerosis. Check back here for ongoing coverage, or subscribe to our e-mails for conference updates.e-mails for conference updates.

Coverage

Dr Paul Wicks Points to the Benefits of Technology in MS Research
   |    ectrims2014
Paul Wicks, PhD, vice president of innovation at PatientsLikeMe, discussed the benefits of using technology in multiple sclerosis research by patients, providers, researchers, and other decision-makers.
   |    ectrims2014 > Laura Joszt
Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
   |    ectrims2014 > Laura Joszt
As a medium, the Internet neither helps nor harms in multiple sclerosis care — what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of innovation at PatientsLikeMe.
Dr Alasdair Coles on the Effectiveness of Alemtuzumab in Treating MS
   |    ectrims2014
At this year’s ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis.
   |    ectrims2014 > Laura Joszt
The second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis reported positive interim results with 70% of patients not requiring a third course of treatment.
   |    ectrims2014 > Laura Joszt
Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
   |    ectrims2014 > Laura Joszt
Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
   |    ectrims2014 > Laura Joszt
The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Feature
$vacMongoViewPlus$